INRC Program Book International Narcotics Research Conference July 9-14, 2017 | Chicago IL USA Hyatt Centric Magnificent Mile INRC Executive Committee Fred Nyberg (Sweden, President) John Traynor (USA, Past-President) Larry Toll (USA, Treasurer) Craig W. Stevens (USA, Information Officer) Cathy Cahill (USA) Amynah Pradhan (USA) Jim Zadina (USA) Chris Bailey (UK) Lucia Hipolito (Spain) Christoph Stein (Germany) Paul Bigliardi (Singapore) Meritxell Canals (Australia) Kazutaka Ikeda (Japan) Organizing Committee Amynah Pradhan (USA) Ream Al-Hasani (USA) Michael Bruchas (USA) Cathy Cahill (USA) Louis Gendron (Canada) Susan Ingram (USA) Emily Jutkiewicz (USA) Nicolas Massaly (USA) Michael Morgan (USA) Jose Moron-Concepcion (USA) Manojkumar Puthenveedu (USA) Tuan Trang (Canada) John Traynor (USA) Richard van Rijn (USA) Adie Wilson-Poe (USA) Contents Pages Exhibitor & Sponsor Information……………………………… 2-3 Location Map…………………………………………………… 4 INRC 2017 Awardees………………………………………… . 5-6 Meeting Schedule……………………………………………… 7-13 List of Posters……………………………………………………14-23 Abstracts………………………………………………………… 24-103 Photographic Policy Please note that photographs taken at this meeting may be used on our website, social networking sites, and in other publications. If you do not wish to have your image used for this purpose, please speak to a member of the INRC Executive Committee or email [email protected]. 1 Thank You to our Generous Sponsors! 2 3 4 INRC 2017 AWARDEES Founders’ Award – Professor John Traynor Dr. John Traynor is Professor of Pharmacology and Associate Chair for Research at the University of Michigan Medical School. He holds the Edward F Domino Research Professorship in Pharmacology and is Principal Investigator of a NIDA-funded training grant on the biology of drug abuse and holder of a NIDA Merit Award. Also, Dr. Traynor chairs the Neuropharmacology Division of the American Society for Pharmacology and Experimental Therapeutics and is a standing member of Neurobiology of Motivated Behavior Study Section of CSR (Center for Scientific Review) of the National Institutes of Health. He has served as Director of the University of Michigan Substance Abuse Research Centre for a four years term and was a member of the Medical School’s Biomedical Research Council from 2010-2016. Dr. Traynor was a permanent member of The National Institute on Drug Abuse (NIDA) Training and Career Development Committee and has served on the editorial boards of Journal of Neurochemistry and the Journal of Medicinal Chemistry. He is currently on the editorial board of the British Journal of Pharmacology. Dr. Traynor earned degrees in Pharmacy (B.S.) and Medicinal Chemistry (Ph.D.), both from the University of Aston in the United Kingdom. His post-doctoral training at the University of Gottingen in Germany concentrated on Biochemical Pharmacology. For more than nearly three decades, Dr. Traynor’s research has focused on opioids and includes areas such as structure-activity relationships, signaling and behavior. He has trained a large number of PhD students and postdoctoral fellows as well as many Masters and Undergraduate students. Dr. Traynor’s laboratory employs a wide range of techniques from molecular biology to behavioral pharmacology. Strong analgesic drugs such as morphine are extremely important both for the treatment of pain and for the medical and social consequences of opiate (heroin) addiction. The laboratory uses in vitro and in vivo models to characterize the mechanism of action of these drugs. In recent years, Dr. Traynor’s research has focused on alternative ways to better harness the analgesic effects of endogenous opioid peptides by targeting a specific family of intracellular proteins (RGS proteins) that act as negative regulators of a variety of neurotransmitters, and/or developing allosteric compounds that modulate opioid receptors in unique ways. The long-term aim of these studies is to identify novel targets and medications to treat pain, drug dependence and depression. Dr. Traynor is also widely appraised for his role in organizing symposia in national and international conferences. He has been a frequent attendant at the INRC meetings throughout his career and together with his students and collaborators provided outstanding contributions to our organization. He was President of the International Narcotics Research Conference (INRC, 2010- 2014) and continues to serve on the Executive Committee of INRC as the immediate past president. Over the years he has really been an active attendant at the INRC meetings and participated in discussion of actual topics in a way that reveal an outstanding competence and experience in questions related to the field of opioids. Unambiguously, Dr. Traynor belongs to the core of successful and prominent researchers that has been essential for development and maintenance of INRC as an organization promoting high-quality science in the area of opioid research. 5 Young Investigators Award – Dr. Aashish Manglik Dr. Aashish Manglik is currently a Stanford Distinguished Fellow and Instructor of Molecular and Cellular Physiology at Stanford University School of Medicine. He has an independent position in which he has his own laboratory and funding, including an Early Independence Award from the NIH Director. Dr. Manglik has been recognized for his work on G protein-coupled receptor signaling and in in silico drug discovery. His work has elucidated the structural basis of opioid receptor function, thereby yielding insight into the mechanism of action of fundamental and widely used analgesics like morphine and codeine. Using these structures, he has pioneered the development of novel opioid analgesics, identified by in silico methods, which potentially possess reduced dose-limiting side effects. Dr. Manglik’s work has been published in more than twenty peer-reviewed articles, and he was a key contributor to the invention of the core technologies at a company he co-founded called Ab Initio Biotherapeutics. Dr. Manglik received his B.A. in Biology and Chemistry at Washington University in St. Louis, where he was awarded the Spector Prize for his outstanding academic and research achievements. At Stanford, he was awarded an American Heart Association Pre-doctoral Fellowship in 2012. In his research there, Dr. Manglik used biophysical techniques such as X-ray crystallography and NMR spectroscopy. Obtaining purified opioid receptors and subsequent crystal structures is a tremendous achievement and requires the very highest abilities and perseverance. These results also rely on the development of new tools to stabilize these challenging proteins. Several of his papers and patents describe the development and design of single domain antibodies (nanobodies) for different conformational states of the mu-opioid receptor. Dr. Manglik trained as an MD as well as a PhD, and his medical training allows him to cover a broad picture generated by the uncovering of these structures. For example, his most recent achievement, and work that he presented at INRC 2016, has been published in Nature. It describes the structure-based discovery of PZM21, an opioid with reduced side-effects in rodent models. This was a mammoth effort across the laboratories of prominent and well-reputed scientists and demonstrates not only Dr. Manglik’s ability to interact and collaborate with top researchers but also his breadth of knowledge. Dr. Manglik has presented many of his findings at meetings and universities in the US but also abroad, e.g. at the above mentioned INRC meeting in Bath (UK) in 2016. At the meeting in Bath, he gave a highly impressive talk on his work on the mu-opioid receptor structure and the discovery of PZM21. His engagement at this meeting attracted many INRC members and his creative attitude will certainly bring an excitement to INRC and encourage other young scientists working in related areas to become regular attendees. 6 Schedule for INRC 2017 Sunday July 9, 2017 3:00-5:30 PM - Registration 5:30-6:00 PM – Pre-welcome reception for trainees 6:00-8:00 PM - Welcome Reception Monday July 10, 2017 7:00-8:30 AM - Breakfast 8:15-8:30 AM - Welcome Address Plenary Lecture 8:30-9:30 AM - Mark von Zastrow – University of California San Francisco, CA, USA - Cell biology of opioid drug action Opioid Receptor Trafficking & Signaling Chair: Aki Ozawa - Torrey Pines Institute, FL, USA Discussion Leader: Louis Gendron – Université de Sherbrooke, QC, Canada 9:30-9:55 AM – Manoj Puthenveedu – Carnegie Mellon University, PA, USA- Endocytic control of functional selectivity of opioid receptors 9:55-10:20 AM – Lee-Yuan Liu-Chen – Temple University, PA, USA– Characterization of a mutant mouse line expressing a fusion protein of kappa opioid receptor and tdTomato 10:20-10:35 AM – Hot Topic 1 – Dominique Massotte - Institut des Neurosciences Cellulaires et Integratives, Strasbourg, France - Trafficking & signaling of endogenous mu-delta heteromers. 10:35-10:55 AM - Coffee Break 10:55-11:20 AM - Nathaniel Jeske – University of Texas Health Science Center at San Antonio, TX, USA – Peripheral Opioid Receptor Regulation 11:20-11:45 AM - Meritxell Canals – Monash University, Melbourne, Australia - GPCR signaling platforms for pain and analgesia 11:45-12:00 PM – Hot Topic 2 - Marta Filizola - Icahn School of Medicine at Mount Sinai, NY, USA - Structural and Dynamic Elements of µ-Opioid Receptor Functional Selectivity 7 12:00-12:15 PM – Hot Topic 3 – William Birdsong – Oregon Health and Sciences University, OR, USA - Opioid modulation of synaptic transmission